Recombinant staphylokinase variants with altered immunoreactivity. II: Thrombolytic properties and antibody induction

Circulation

Volumn 94, Issue 2, 1996, Pages 207-216

  Collen, Désiré ^a   Moreau, Huberte ^a   Stockx, Luc ^b   Vanderschueren, Steven ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

antibodies; immunology; staphylokinase

Indexed keywords

FREUND ADJUVANT; RECOMBINANT PROTEIN; STAPHYLOKINASE;

ADULT; AGED; ANTIBODY RESPONSE; ARTERY THROMBOSIS; ARTICLE; BLOOD CLOT LYSIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ANTIGENICITY; DRUG DISPOSITION; DRUG HALF LIFE; DRUG SAFETY; FEMALE; FIBRINOLYTIC THERAPY; HAMSTER; HUMAN; ILIAC ARTERY; IMMUNOGENICITY; INTRAARTERIAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LUNG EMBOLISM; MALE; NONHUMAN; POPLITEAL ARTERY; PRIORITY JOURNAL; RABBIT; SUBCUTANEOUS DRUG ADMINISTRATION; SUPERFICIAL FEMORAL ARTERY;

EID: 0029896802     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.94.2.207     Document Type: Article

References (21)

1. Collen D, Lijnen HR. Basic and clinical aspects of fibrinolysis and thrombolysis. Blood. 1991;78:3114-3124.
2. Collen D, Lijnen HR. Staphylokinase. a fibrin-specific plasminogen activator with therapeutic potential? Blood. 1994;84:680-686.
3. Collen D, Zhao ZA, Holvoet P, Marynen P. Primary structure and gene structure of staphylokinase. Fibrinolysis. 1992;6:226-231.
4. Collen D, De Cock F, Vanlinthout I. Declerck PJ, Lijnen HR, Stassen JM. Comparative thrombolytic and immunogenic properties of staphylokinase and streptokinase. Fibrinolysis. 1992;6:232-242.
5. Collen D, De Cock F, Stassen JM. Comparative immunogenicity and thrombolytic properties toward arterial and venous thrombi of streptokinase and recombinant staphylokinase in baboons. Circulation. 1993;87:996-1006.
6. Collen D, Van de Werf F. Coronary thrombolysis with recombinant staphylokinase in patients with evolving myocardial infarction. Circulation. 1993;87:1850-1853.
7. Schlott B, Hartmann M, Gührs KH, Birch-Hirschfeld E, Pohl HD, Vanderschueren S, Van de Werf F, Michoel A, Collen D, Behnke D. High yield production and purification of recombinant staphylokinase for thrombolytic therapy. Biotechnology. 1994;12:185-189.
8. Vanderschueren S, Barrios L, Kerdsinchai P, Van den Heuvel P, Hermans L, Vrolix M, De Man F, Benit E, Muyldermans L, Collen D, Van de Werf F. A randomized trial of recombinant staphylokinase versus alteplase for coronary artery patency in acute myocardial infarction. Circulation. 1995;92:2044-2049.
9. Vanderschueren S, Stockx L, Wilms G, Lacroix H, Verhaeghe R, Vermylen J, Collen D. Thrombolytic therapy of peripheral arterial occlusion with recombinant staphylokinase. Circulation. 1995; 92:2050-2057.
10. Collen D, Bernaerts R, Declerck P, De Cock F, Demarsin E, Jenné S, Laroche Y, Lijnen HR, Silence K, Verstreken M. Recombinant staphylokinase variants with altered immunoreactivity, I: construction and characterization. Circulation. 1996;94:197-206.
11. Silence K, Hartmann M, Gührs KH, Gase A, Schlott B, Collen D, Lijnen HR, Structure-function relationships in staphylokinase as revealed by 'clustered charge-to-alanine' mutagenesis. J Biol Chem. 1995;270:27192-27198.
12. Collen D, Silence K, Demarsin E, De Mol M, Lijnen HR. Isolation and characterization of natural and recombinant staphylokinase. Fibrinolysis. 1992;6:203-213.
13. Nakane PK, Kawaoi A. Peroxidase-labeled antibody: a new method of conjugation. J Histochem Cytochem. 1974;22:1084-1091.
14. Matsuo O, Rijken DC, Collen D. Comparison of the fibrinogenolytic, fibrinolytic and thrombolytic properties of tissue plasminogen activator and urokinase in vitro. Thromb Haemost. 1981;45:225-229.
15. Stassen JM, Vanlinthout I, Lijnen HR, Collen D. A hamster pulmonary embolism model for the evaluation of the thrombolytic and pharmacokinetic properties of thrombolytic agents. Fibrinolysis. 1990;4:15-21.
16. Gibaldi M, Perrier D, Pharmacokinetics. New York, NY: Marcel Dekker; 1983:45-111.
17. De Clerck F, Beetens J, de Chaffoy de Courcelles D, Freyne E, Janssen PA. R68070: thromboxane A2 synthetase inhibition and thromboxane A2/prostaglandin endoperoxide receptor blockade combined in one molecule, I: biochemical profile in vitro. Thromb Haemost. 1989;61:35-42.
18. Collen D, Lijnen HR, Vanlinthout I, Kieckens L, Nelles L, Stassen JM, Thrombolytic and pharmacokinetic properties of human tissuetype plasminogen activator variants, obtained by deletion and/or duplication of structural/functional domains in a hamster pulmonary embolism model. Thromb Haemost. 1991;65:174-180.
19. Giles AR. Guidelines for the use of animals in biomedical research. Thromb Haemost. 1987;58:1078-1084.
20. Declerck PJ, Vanderschueren S, Billiet J, Moreau H, Collen D. Relevance and induction of circulating antibodies against recombinant staphylokinase. Thromb Haemost. 1994;71:129-133.
21. Vanderschueren SMF, Stassen JM, Collen D. On the immunogenicity of recombinant staphylokinase in patients and in animal models. Thromb Haemost. 1994;72:297-301.